RxDoctor Payments Data

Elizabeth Martin, MD

Family Medicine · Columbus, GANPI 1851405005

Payments from drug & device makers

$13,565in general payments, 2019–2025

Across 562 payments — averaging $24.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4K
  • GSK$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AbbVie$842
  • AstraZeneca$807
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$3,45025%
  • Food & beverage$9,94373%
  • Education$1721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,565 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$228,617
Medicare patients
368
Services billed
4,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide68$102,240
OzempicSemaglutide36$88,561
JardianceEmpagliflozin67$69,181
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$42,750
JanuviaSitagliptin Phosphate39$39,997
FarxigaDapagliflozin Propanediol47$35,313
MyrbetriqMirabegron30$28,737
VascepaIcosapent Ethyl51$25,507
EliquisApixaban26$23,531
LinzessLinaclotide13$21,395
MounjaroTirzepatide11$19,796
NexletolBempedoic Acid14$9,944
EntrestoSacubitril/Valsartan15$9,235
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$6,766
Pitavastatin Calcium20$6,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,045$190,801104 claims
Boehringer IngelheimJardiance$574$69,18167 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,204$48,76443 claims
MerckJanuvia, Janumet Xr$110$46,31050 claims
AstraZenecaFarxiga$807$35,31347 claims
Astellas Pharma US IncMyrbetriq$373$28,73730 claims
AbbVieLinzess, Synthroid$842$27,00165 claims
PfizerEliquis$4,188$23,53126 claims
Lilly USA, LLCMounjaro$1,038$19,79611 claims
Esperion Therapeutics, Inc.Nexletol$107$9,94414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →